As reported in The Lancet by Lu et al, an interim analysis of the Chinese phase III HARMONi-6 trial showed that ivonescimab plus chemotherapy was associated with significantly improved overall survival vs tislelizumab plus chemotherapy in patients with previously untreated advanced squamous non–small cell lung cancer (NSCLC). A prior report from the trial showed that progression-free survival, the primary endpoint, was significantly better with ivonescimab plus chemotherapy.

An investigational targeted therapy designed to block one of the most common genetic drivers of pancreatic cancer has shown promising early results when combined with standard first-line chemotherapy, according to research presented at the ESMO Gastrointestinal Cancers Congress 2026 (Abstract 340O).

On July 14, the U.S. Food and Drug Administration (FDA) granted traditional approval to selpercatinib (Retevmo), an oral RET inhibitor, for adult and pediatric patients aged 2 years and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, whose disease has progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. Selpercatinib received accelerated approval for this indication for adult patients in 2022 and for pediatric patients aged 2 years and older in 2024.

New findings in a report led by the American Cancer Society (ACS) reveal an urgent picture of a growing global cancer burden and underscore the life-saving potential of stronger prevention and equitable access to care. According to Global Cancer Statistics, 2026, nearly 21 million people were diagnosed with cancer and 9.8 million died from the disease globally in 2024. The estimates show about 1 in 5 people worldwide will develop cancer during their lifetime; 1 in 9 men and 1 in 13 women will die from the disease. The number of cancer cases is projected to reach 34 million by 2050—a 67% increase from 2024—solely based on population aging and growth.